Second Sight Medical Products Inc. (EYES) Trading 6% Higher
Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) traded up 6% on Tuesday . The company traded as high as $4.55 and last traded at $4.40, with a volume of 981,100 shares traded. The stock had previously closed at $4.15.
Separately, Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th.
The company’s market capitalization is $151.72 million. The firm’s 50 day moving average is $3.82 and its 200 day moving average is $4.57.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period last year, the business earned ($0.12) EPS. The company earned $1.05 million during the quarter, compared to the consensus estimate of $1.38 million. The firm’s quarterly revenue was down 38.2% compared to the same quarter last year. Analysts forecast that Second Sight Medical Products Inc. will post ($0.65) EPS for the current fiscal year.
In related news, Chairman Robert J. Greenberg sold 8,223 shares of the stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $5.27, for a total transaction of $43,335.21. Following the completion of the sale, the chairman now owns 181,134 shares in the company, valued at $954,576.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Robert J. Greenberg sold 8,571 shares of the stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $4.10, for a total value of $35,141.10. Following the sale, the chairman now owns 172,911 shares of the company’s stock, valued at approximately $708,935.10. The disclosure for this sale can be found here.
An institutional investor recently bought a new position in Second Sight Medical Products stock. Zeke Capital Advisors LLC bought a new stake in Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, according to its most recent disclosure with the SEC. The fund bought 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products makes up about 2.5% of Zeke Capital Advisors LLC’s holdings, making the stock its 10th largest position. Zeke Capital Advisors LLC owned 1.38% of Second Sight Medical Products at the end of the most recent reporting period.
Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.